Clinical Trial Update: Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2a study evaluating safety, tolerability, and pharmacokinetics of topically applied PRN473 (SAR444727) in mild-to-moderate atopic dermatitis completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• PRN473 (SAR444727)

Snippet

Sponsor: Principia Biopharma, a Sanofi Company | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-03-01